Organization and running of the first comprehensive hereditary cancer clinic in India

Hereditary Cancer in Clinical Practice

Volumn 3, Issue 4, 2005, Pages 165-170

  Rajkumar, T ^a   Soumittra, N ^a   Vidubala, E ^a   Sridevi, V ^a   Mahajan, V ^a   Ramanan, S G ^a   Vijaya, S ^a  

^a CANCER INSTITUTE WIA   (India)

Author keywords

dHPLC; Hereditary cancer clinic; Hereditary cancers; India; Mutation analysis; Social issues

Indexed keywords

BRCA2 PROTEIN; PROTEIN MLH1; PROTEIN MSH2;

BRCA2 GENE; BREAST CANCER; CANCER CENTER; COLORECTAL CANCER; FAMILIAL CANCER; GENE MUTATION; HMLH1 GENE; HMSH2 GENE; HUMAN; INDIA; ONCOGENE; OVARY CANCER; REVIEW;

EID: 29944441147     PISSN: 17312302     EISSN: None     Source Type: Journal    
DOI: 10.1186/1897-4287-3-4-165     Document Type: Review

References (14)

1. Shanta V and Swaminathan R Cancer incidence and mortality in Chennai, India 2002. National Cancer registry program, Cancer Institute (WIA), Chennai 2005.
2. Ferlay J, Bray F, Pisani P, Parkin DM, GLOBOCAN 2002. Cancer incidence, mortality and prevalence worldwide. IARC Cancerbase No. 5, version 2.0, IARC press, Lyon 2004.
3. Saxena S, Szabo CI, Chopin S, Barjhoux L, Sinilnikova O, Lenoir G, Goldgar DE and Bhatanager D. BRCA1 and BRCA2 in Indian breast cancer patients. Hum Mutat; 2002; 20: 473-474.
4. Kumar BV, Lakhotia S, Ankathil R, Madhavan J, Jayaprakash PG, Nair MK and Somasundaram K. Germline BRCA1 mutation analysis in Indian breast/ovarian cancer families. Cancer Biol Ther 2002; 1: 18-21.
5. Rajkumar T, Soumittra N, Nancy NK, Swaminathan R, Sridevi V and Shanta V. BRCA1, BRCA2 and CHEK2 (1100 del C) germline mutations in hereditary breast and ovarian cancer families in South India. Asian Pac J Cancer Prev 2003; 4: 203-208.
6. Rajkumar T, Soumittra N, Pandey D, Nancy KN, Mahajan V and Majhi U. Mutation analysis of hMSH2 and hMLH1 in colorectal cancer patients in India. Genet Test 2004; 8: 157-162.
7. Gould RL, Lynch HT, Smith RA, McCarthy JF. Cancer and Genetics. Answering your patients questions. A manual for clinicians and their patients. American Cancer Society and PRR Inc. 1998; Chapter 6, 59-65.
8. Rodriguez-Bigas MA, Boland CR, Hamilton SR, Henson DE, Jass JR, Khan PM, Lynch H, Perucho M, Smyrk T, Sobin L and Srivastava S. A National Cancer Institute Workshop on Hereditary Nonpolyposis Colorectal Cancer Syndrome: meeting highlights and Bethesda guidelines. J Natl Cancer Inst 1997; 89: 1758-1762.
9. Eng C, Clayton D, Schuffenecker I, Lenoir G, Cote G, Gagel RF, van Amstel HK, Lips CJ, Nishisho I, Takai SI, Marsh DJ, Robinson BG, Frank-Raue K, Raue F, Xue F, Noll WW, Romei C, Pacini F, Fink M, Niederle B, Zedenius J, Nordenskjold M, Komminoth P, Hendy GN, Mulligan LM, et al. The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis. JAMA 1996; 276: 1575-1579.
10. Li FP, Fraumeni JF Jr. Soft-tissue sarcomas, breast cancer, and other neoplasms. A familial syndrome? Ann Intern Med 1969; 71: 747-752.
11. Eeles RA. Germline mutations in the TP53 gene. Cancer Surv 1995; 25: 101-124.
12. Padberg BC, Schroder S, Jochum W, Kastendieck H, Roth J, Heitz PU and Komminoth P. Absence of RET proto-oncogene point mutations in sporadic hyperplastic and neoplastic lesions of the parathyroid gland. Am J Pathol 1995; 147: 1600-1607.
13. Vet JA, Bringuier PP, Poddighe PJ, Karthaus HF, Debruyne FM and Schalken JA. p53 mutations have no additional prognostic value over stage in bladder cancer. Br J Cancer 1994; 70: 496-500.
14. Verselis SJ, Rheinwald JG, Fraumeni JF Jr and Li FP. Novel p53 splice site mutations in three families with Li-Fraumeni syndrome. Oncogene 2000; 19: 4230-4235.